Evidence map›Paper›PMID 39385303›Full record

ArticleJournal of nanobiotechnology2024

Construction of in-situ self-assembled agent for NIR/PET dual-modal imaging and photodynamic therapy for hepatocellular cancer.

Xinmiao Lu, Yucheng Fu, Yunyun Zhu, Chuang Xi, Quanyong Luo, Hua Pang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xinmiao LuDepartment of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China.
Yucheng FuDepartment of Orthopaedic, School of Medicine, Ruijin Hospital, Affiliated to Shanghai Jiao Tong University, Shanghai, 200025, China.
Yunyun ZhuDepartment of Nuclear Medicine, Shanghai Sixth People's Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200235, P. R. China.
Chuang XiDepartment of Nuclear Medicine, Shanghai Sixth People's Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200235, P. R. China.
Quanyong LuoDepartment of Nuclear Medicine, Shanghai Sixth People's Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200235, P. R. China. luoqy@sjtu.edu.cn.
Hua PangDepartment of Nuclear Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, P. R. China. ph1973@126.com.

Funding

National Natural Science Foundation of China 81974271
6 · The paper itself

Abstract

Hepatocellular cancer (HCC) remained a life-threatening carcinoma. Agents for HCC imaging and therapy were expected to possess different intratumoral retention time. To construct an agent with different intratumoral retention time when applied for tumor imaging or therapy remained great values. A lasialoglycoprotein receptor (ASGPR) targeted lactobionic acid derivative (LABO) was constructed for fluorescent imaging and photodynamic therapy of HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsPhotochemotherapyPositron-Emission TomographyAnimalsDisaccharidesFluorine RadioisotopesHep G2 CellsHumansMiceMice, Inbred BALB CMice, NudeOptical ImagingPhotosensitizing AgentsTissue DistributionDisaccharidesFluorine Radioisotopeslactobionic acidPhotosensitizing AgentsASGPRIn-situ self-assemblyLactobionic acidPET imagingPhotodynamic therapy

Identifiers

PMID39385303
PMCPMC11465773

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.